Your browser doesn't support javascript.
Neutralizing antibody: a savior in the Covid-19 disease.
Gupta, Sneh Lata; Jaiswal, Rishi Kumar.
  • Gupta SL; Department of Pediatrics, Division of Infectious Disease, School of Medicine, Emory University, Atlanta, GA, 30322, USA.
  • Jaiswal RK; Department of Cancer Biology, Cardinal Bernardin Cancer Center, Loyola University Chicago Stritch School of Medicine, Maywood, IL, 60153, USA. rishijai24@gmail.com.
Mol Biol Rep ; 49(3): 2465-2474, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1605165
ABSTRACT
Coronavirus outbreak was declared a pandemic by World Health Organization (WHO) in March 2020. The pandemic has led to a devastating loss of life. It has shown us how infectious diseases can cause human existence at stake, and community health is important. The spike protein is the most immunogenic component of the virus. Most vaccine development strategies have focused on the receptor-binding domain (RBD) in the spike protein because it is the most specific target site that recognizes and interacts with human lung cells. Neutralizing antibodies are generated by the humoral immune system and reduce the viral load by binding to spike protein components. Neutralizing antibodies are the proteins secreted by plasma cells and serve as an important part of the defense mechanism. In the recent Covid-19 infection, neutralizing antibodies can be utilized for both diagnostic such as immune surveillance and therapeutic tools such as plasma therapy. So far, many monoclonal antibodies are in the clinical trial phase, and few of them are already in use. In this review, we have discussed details about neutralizing antibodies and their role in combating Covid-19 disease.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Mol Biol Rep Year: 2022 Document Type: Article Affiliation country: S11033-021-07020-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Mol Biol Rep Year: 2022 Document Type: Article Affiliation country: S11033-021-07020-6